Three-month Clinical Status of A Cohort of Adult Hospitalized COVID-19 Pimpaka Srisiriwanna M.D., Poolsuk Janepanish Visudtibhan Ph.D., Kumthorn Malathum M.D
Journal of Infectious Diseases and Antimicrobial Agents
; 40(1):1-12, 2023.
Article
Dans Anglais
| GIM | ID: covidwho-20243226
ABSTRACT
Background:
A significant portion of individuals with SARS-CoV-2 infection have persistent COVID-19 symptoms after recovery. Symptoms may be new or persistent from the initial illness, which could cause both psychological and physical difficulty to the patients. These symptoms are collectively known as "long COVID-19 syndrome". There is limited information about this syndrome in the Thai population.Objectives:
We aimed to describe and evaluate the risk for post COVID-19 symptoms among hospitalized COVID-19 patients in a university hospital.Methods:
A prospective descriptive study was conducted on symptomatic COVID-19 patients admitted in Ramathibodi Hospital from July 1 to September 10, 2021. All surviving COVID-19 patients received a telephone assessment every month until 3 months after discharge and electronic medical records were reviewed. Information collected included symptoms, severity, treatment, duration of symptom, complication of COVID-19 and treatment. The New York Heart Association (NYHA) functional classification was used to categorized severity of dyspnea.Results:
Among 253 evaluable patients, 57.3% were female and the mean age was 59.3 years old. Of these, 66% and 24.1% had moderate (pneumonia and SpO2 90%) and severe COVID-19 (pneumonia with severe respiratory distress and SpO2 90%), respectively. Almost all patients were inadequately vaccinated (unvaccinated 53.3%, partially vaccinated 41.9%). Overall, complete resolution of symptoms before 1 month after onset were noted in 47 patients (18.5%) and 72 (28.5%) patients had at least one persistent symptom at three months. The most common symptom is sleep disturbance (11.9%);29.2% remain in NYHA II and 0.8% in NYHA III and IV each. Female gender (OR 1.94;[95% CI 1.09-3.48], p=0.024), history of receiving dexamethasone (OR 1.04;[95% CI 1.01-1.08], p=0.004) and length of hospitalization (OR 1.04;[95% CI 1.00-1.08], p=0.034) were associated with being in NYHA II. Additionally, 5.9% had bacterial infection, and most were urinary tract infection and pneumonia, respectively. The risk factor associated with post-COVID-19 bacterial infection is bed ridden status (OR 23.3;[95% CI 5.79-93.72], p=<0.001).Conclusions:
A significant number of COVID-19 patients had residual COVID-19 symptoms and still not fully functional at least 3 months after recovery. A major limitation of this study is obtaining information by telephone interview since hospital visit were not encouraged to limit mobility of people during pandemic, which may have led to a recall bias.
human diseases; coronavirus disease 2019; viral diseases; symptoms; pandemics; risk factors; clinical aspects; Severe acute respiratory syndrome coronavirus 2; man; New York; USA; Severe acute respiratory syndrome-related coronavirus; Betacoronavirus; Coronavirinae; Coronaviridae; Nidovirales; positive-sense ssRNA Viruses; ssRNA Viruses; RNA Viruses; viruses; Homo; Hominidae; primates; mammals; vertebrates; Chordata; animals; eukaryotes; Middle Atlantic States of USA; Northeastern States of USA; APEC countries; high income countries; North America; America; OECD Countries; very high Human Development Index countries; SARS-CoV-2; viral infections; clinical picture; United States of America
Collection:
Bases de données des oragnisations internationales
Base de données:
GIM
Type d'étude:
Étude de cohorte
/
Études expérimentales
/
Étude observationnelle
/
Étude pronostique
Les sujets:
Covid long
/
Vaccins
langue:
Anglais
Revue:
Journal of Infectious Diseases and Antimicrobial Agents
Année:
2023
Type de document:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS